J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?

Johnson & Johnson's Innovative Medicine sales grew 6.2% organically in the first half of 2026 despite Stelara's loss of exclusivity, while new oncology drugs generated $2.6 billion in sales and management reaffirmed its approximately $100 billion 2026 revenue target after generating $49.4 billion in the first half. J&J agreed to a $5.5 billion settlement covering nearly all remaining talc litigation, though effectiveness requires 95% claimant-firm participation and payments could begin at up to $3 billion in 2027. Offsetting risks include Stelara biosimilar erosion, upcoming Simponi and Opsumit patent expirations, and moderating MedTech growth, where Q2 sales rose 4.5% to $8.93 billion and Abiomed sales fell 2%. Shares are up 30.6% year to date and trade at 21.69x forward earnings versus the industry's 18.01x, supporting a hold-oriented assessment despite modest upward EPS estimate revisions.

Analysis

JNJ’s rerating now requires execution rather than merely removal of uncertainty. The negligible upward movement in forward EPS estimates is inconsistent with a premium multiple, leaving the shares vulnerable over the next 1-3 months if launch uptake fails to produce meaningful guidance increases; a return toward its historical valuation would outweigh modest earnings beats. The settlement remains a contingent liability until claimant participation is confirmed, and scheduled cash payments could reduce flexibility for bolt-on M&A or incremental capital returns in 2027-28.

The more investable read-through is competitive: an effective oral IL-23 option could pressure AbbVie’s (ABBV) injectable Skyrizi franchise and Bristol Myers’ (BMY) Sotyktu in psoriasis, where payer access and persistence—not initial prescription demand—will determine value. PTGX has potentially superior upside to JNJ from successful commercialization because its economics are concentrated in the partnered asset, but this also makes it highly exposed to launch cadence, royalty disclosures, and any change in JNJ’s promotional priority. Treat peak-sales claims as unverified until quarterly new-to-brand share and formulary wins are disclosed.

MedTech weakness is unlikely to be earnings-material alone, but it changes the quality of JNJ’s growth mix: pharma growth carries greater patent-duration and reimbursement risk, while a prolonged slowdown in high-risk PCI procedures could create a 2027 clinical-data binary. Contrarian view: the market may be underpricing the chance that biosimilar erosion and upcoming loss-of-exclusivity events overlap before new launches achieve durable scale, rather than occurring as cleanly offsetting events.

Key Decisions for Investors

• Do not add outright JNJ after the rerating; maintain only market-weight exposure through the next earnings print. Add only if management raises 2027 EPS/revenue guidance materially or the stock retraces enough to narrow the forward P/E premium toward the large-pharma peer group; thesis is falsified by sustained launch-share acceleration plus a credible 2027 growth upgrade.
• Initiate a 3-6 month relative-value hedge: long ABBV / short JNJ in equal dollar amounts. ABBV offers more visible near-term cash-flow support, while JNJ bears premium-multiple and litigation-finalization risk; close if JNJ’s new-launch sales visibly accelerate enough to drive upward consensus revisions or if ABBV’s immunology guidance weakens.
• Place PTGX on a catalyst watch rather than buy blindly. Initiate only after independently measurable prescription/formulary data confirm oral IL-23 adoption and management quantifies partner economics; use a small, high-volatility position because a slower launch could materially impair royalty expectations.
• Monitor talc claimant-participation progress and JNJ’s 2027 cash-flow bridge. Failure to reach the required threshold, a larger-than-expected reserve, or incremental litigation costs would be a clear trigger to reduce JNJ exposure; successful finalization is likely already substantially reflected in the multiple.